Preventive effect of Metformin against N-nitrosodiethylamine-initiated hepatocellular carcinoma in rats
Open accessAbstract
Effect of Metformin in chemically induced hepatocarcinogenesis was assessed in Wistar rats. Intraperitoneal administration of chemical carcinogen diethyl nitrosamine (DENA) (200 mg/kg) in single dose elevated the levels of serum glutamate oxaloacetate transaminase (SGOT), serum glutamate pyruvate transaminase (SGPT), alkaline phosphatase (ALP), total cholesterol (TC), triglycerides (TG) and reduced high density lipoproteins (HDL), total proteins (TPR) and blood glucose level in tested animals. Histopathological examinations of the liver tissue showed marked carcinogenicity of the chemical carcinogen. Food and water intake, animal weights and serum albumin (ALB) were also assessed. The animals exposed to DENA showed a significant decrease in the body weights and, there were no significant alterations found in the total bilirubin (TBR) levels and gamma-glutamyltranspeptidase (GGTP), whereas the decreased levels of serum ALB were maintained by Metformin treatment. The elevated levels of serum SGOT, SGPT, ALP, AFP, TC and TG were restored by administration of Metformin in reduced dose (125 mg/kg) daily for 16 weeks p.o. Physiological and biochemical analysis showed the beneficial effects of Metformin in the animals exposed to DENA.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
This epidemiologic evidence has coalesced with experimental work in animals.
“This epidemiologic evidence has coalesced with experimental work in animals(256–263).”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [259]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Estimating the world cancer burden: Globocan 2000
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2001) · International Journal of Cancer · doi:10.1002/ijc.1440 · Cited by 3,718 · see citing works
Llovet, J. M., Burroughs, A. K., & Bruix, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14964-1 · Cited by 3,613 · see citing works
Rising Incidence of Hepatocellular Carcinoma in the United States
El‐Serag, H. B., & Mason, A. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401001 · Cited by 2,865 · see citing works
Hépatocellulaire, G. D. E. D. T. D. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505113321903 · Cited by 800 · see citing works
Polyunsaturated fatty acids (PUFA) and eicosanoids in human health and pathologies
Tapiero, H., Ba, G. N., Couvreur, P., & Tew, K. D. (2002) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(02)00193-2 · Cited by 632 · see citing works
Bartsch, H., Nair, J., & Owen, R. W. (1999) · Carcinogenesis · doi:10.1093/carcin/20.12.2209 · Cited by 481 · see citing works
Metformin: Multi-faceted protection against cancer
Barco, S. D., Vázquez‐Martín, A., Cufí, S., Oliveras‐Ferraros, C., Bosch‐Barrera, J., Joven, J., Martı́n-Castillo, B., & Menéndez, J. A. (2011) · Oncotarget · doi:10.18632/oncotarget.387 · Cited by 302 · see citing works
Donadon, V., Balbi, M., Mas, M. D., Casarin, P., & Zanette, G. (2010) · Liver International · doi:10.1111/j.1478-3231.2010.02223.x · Cited by 293 · see citing works
Metformin and cancer: new applications for an old drug
Kourelis, T., & Siegel, R. D. (2011) · Medical Oncology · doi:10.1007/s12032-011-9846-7 · Cited by 288 · see citing works
Chen, G., Xu, S., Renko, K., & Derwahl, M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1754 · Cited by 196 · see citing works
Influence of liver cancer on lipid and lipoprotein metabolism
Jiang, J., Nilsson‐Ehle, P., & Xu, N. (2006) · Lipids in Health and Disease · doi:10.1186/1476-511x-5-4 · Cited by 195 · see citing works
The Increasing Incidence of Hepatocellular Carcinoma
Ince, M. N., & Wands, J. R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401009 · Cited by 192 · see citing works
Impact of Metformin on the Prognosis of Cirrhosis Induced by Viral Hepatitis C in Diabetic Patients
Nkontchou, G., Cosson, E., Aout, M., Mahmoudi, A., Bourcier, V., Charif, I., Ganne‐Carrié, N., Grando–Lemaire, V., Vicaut, É., Trinchet, J., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2415 · Cited by 165 · see citing works
Metformin induces apoptosis of pancreatic cancer cells
Wang, L., Li, Z., Zou, D., Jin, Z., Gao, J., & Xu, G.-M. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.7192 · Cited by 153 · see citing works
Lucier, G. W., Tritscher, A. M., Goldsworthy, T. L., Foley, J., Clark, G., Goldstein, J. A., & Maronpot, R. R. (1991) · PubMed · Cited by 146 · see citing works
Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma
Yeo, W., Mo, F. K. F., Koh, J., Chan, A. T. �., Leung, T., Hui, P., Chan, S. L., Tang, A., Lee, J. J., Mok, T. S. K., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl065 · Cited by 122 · see citing works
ESFAHANIAN, N., SHAKIBA, Y., NIKBIN, B., SORAYA, H., MALEKI-DIZAJI, N., GHAZI-KHANSARI, M., & GARJANI, A. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.753 · Cited by 120 · see citing works
Hepatoprotective and anti-hepatocarcinogenic effects of glycyrrhizin and matrine
Wan, X., Luo, M. B., Li, X., et al. (2009) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2009.04.013 · Cited by 118 · see citing works
Protective effect of diphenyl diselenide on acute liver damage induced by 2-nitropropane in rats
Borges, L. P., Borges, V. C., Moro, A. V., Nogueira, C. W., da Rocha, J. B. T., & Zeni, G. R. (2005) · Toxicology · doi:10.1016/j.tox.2005.01.002 · Cited by 97 · see citing works
p53 mutations and aflatoxin B1 exposure in hepatocellular carcinoma patients from thailand
Hollstein, M. C., Wild, C. P., Bleicher, F., et al. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910530111 · Cited by 96 · see citing works
Metformin hydrochloride: An antihyperglycemic agent
Klepser, T. B., & Kelly, M. W. (1997) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/54.8.893 · Cited by 83 · see citing works
Can tumour cell drug resistance be reversed by essential fatty acids and their metabolites?
Das, U. N., Madhavi, N., Kumar, G. S., et al. (1998) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/s0952-3278(98)90128-4 · Cited by 82 · see citing works
Goodwin, P. J., & Stambolic, V. (2011) · The Breast · doi:10.1016/s0960-9776(11)70291-0 · Cited by 71 · see citing works
Radical‐induced oxidation of metformin
Khouri, H., Collin, F., Bonnefont‐Rousselot, D., Legrand, A., Jore, D., & Gardès-Albert, M. (2004) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.2004.04438.x · Cited by 64 · see citing works
Metformin in Noninsulin‐Dependent Diabetes Mellitus
Lee, A. J. (1996) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1996.tb02964.x · Cited by 61 · see citing works
Abel, S., de Kock, M., Schalkwyk, D. J. V., et al. (2009) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2009.08.003 · Cited by 55 · see citing works
Risk of hepatocellular carcinoma in hepatitis B and prevention through treatment
Carey, W. D., & Sherman, M. (2009) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.76.s3.02 · Cited by 50 · see citing works
Monteagudo, S., Pérez‐Martínez, F. C., Pérez‐Carrión, M. D., Guerra, J., Merino, S., Sánchez‐Verdú, P., & Ceña, V. (2011) · Nanomedicine · doi:10.2217/nnm.11.61 · Cited by 46 · see citing works
Anticancer Effects of Metformin and Its Potential Use as a Therapeutic Agent for Breast Cancer
Guppy, A., Jamal‐Hanjani, M., & Pickering, L. M. (2011) · Future Oncology · doi:10.2217/fon.11.49 · Cited by 42 · see citing works
Premalatha, B., & Sachdanandam, P. (1999) · Fitoterapia · doi:10.1016/s0367-326x(99)00043-x · Cited by 25 · see citing works
Thirunavukkarasu, C., & Sakthisekaran, D. (2003) · Cell Biochemistry and Function · doi:10.1002/cbf.1011 · Cited by 22 · see citing works
Muzio, G., Marengo, B., Salvo, R. A., et al. (1999) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(98)00329-3 · Cited by 21 · see citing works
Supplementation of selenium reduces chemical hepatocarcinogenesis in male Sprague-Dawley rats
Alwahaibi, N., Mohamed, J., & Alhamadani, A. (2009) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2009.09.003 · Cited by 21 · see citing works
Therapeutic effects of metformin in breast cancer: involvement of the immune system?
Schott, S., Bierhaus, A., Schütz, F., Beckhove, P., Schneeweiß, A., Sohn, C., & Domschke, C. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1062-y · Cited by 18 · see citing works
Small HCCs Identified by Screening
Pančoška, P., Giorgio, M. D., FAGIUOLI, S., et al. (2011) · Digestive Diseases and Sciences · doi:10.1007/s10620-011-1687-x · Cited by 10 · see citing works
Small Hepatocellular Carcinoma in Chinese Patients
Carr, B. I., Lu, S., & Pančoška, P. (2011) · Hepatogastroenterology · doi:10.5754/hge11029 · Cited by 9 · see citing works
Gönül, B., Söylemezoğlu, T., & Erbaş, D. (1996) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/s0952-3278(96)90006-x · Cited by 2 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- Llovet, J.M., Burroughs, A., Bruix, J., 2003. Hepatocellular carci- noma. Lancet 362 (9399), 1907-1917.
Cited by
Sorted by citations
Romero, R., Erez, O., Hüttemann, M., Maymon, E., Panaitescu, B., Conde-Agudelo, A., Pacora, P., Yoon, B. H., & Grossman, L. I. (2017) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.06.003 · Cited by 253 · see citing works
- Authors
- Afzal, M., Kazmi, I., Gupta, G., Rahman, M., Kimothi, V., & Anwar, F.
- Corresponding author
- Anwar, Firoz
- Venue
- Saudi Pharmaceutical Journal
- Published
- 2012-10
- Volume
- 20
- Issue
- 4
- Pages
- 365-370
- ISSN
- 1319-0164 (ISSN-L)
- PMC
- PMC3745037
- OpenAlex
- W1982096716
- Cited by
- 45
- References
- 37
- Citations by year
- 2025: 2 · 2024: 7 · 2023: 3 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 9 · 2018: 4 · 2017: 8 · 2016: 1 · 2015: 4 · 2014: 2 · 2013: 1
- FWCI
- 0.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Saudi Pharmaceutical Journal (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer and biochemical research
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Keywords
- metformin, hepatocellular carcinoma, diethylnitrosamine, preventive effect, liver enzymes, serum albumin, liver histopathology, anticancer activity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review